Mayo Medical Laboratories | GenomeWeb

Mayo Medical Laboratories

Mayo Medical Laboratories said this week that it has begun offering mass spec-based serum thyroglobulin testing using SISCAPA technology.

The Mayo Medical Laboratories will now offer Sequenom's MaterniT21 Plus test to patients at high risk for fetal chromosome abnormalities.

BioTheranostics said this week that Mayo Clinic and Mayo Medical Laboratories will offer the company's CancerType ID molecular cancer classification test to aid in the management of patients with metastatic cancer.

NEW YORK (GenomeWeb News) – Mayo Clinic and Mayo Medical Laboratories will offer BioTheranostics' CancerType ID molecular cancer classification test under a deal announced today.

The new test will be based on real-time PCR using fluorescence resonance energy transfer probes for detection.

The technology will allow Mayo to offer a test for M. tuberculosis complex speciation.

The eventual goal of the partnership would be to port the validated assay onto Rheonix's fully automated, modular molecular testing platform, which is still under development but may reduce the complexity and cost of warfarin sensitivity testing.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.